Ocugen Number of Employees 2013-2022 | OCGN

Ocugen number of employees from 2013 to 2022. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
Ocugen Annual Number of Employees
2021 56
2020 15
2019 16
2018 49
2017 45
2016 47
2015 49
2014 42
2013 42
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.352B $0.043B
Ocugen Inc. is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $172.495B 10.52
GSK (GSK) United Kingdom $71.890B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.433B 19.52
Ginkgo Bioworks Holdings (DNA) United States $3.861B 0.00
Myovant Sciences (MYOV) United Kingdom $2.605B 0.00
Arcus Biosciences (RCUS) United States $2.586B 38.81
Biohaven (BHVN) United States $1.141B 0.00
Emergent Biosolutions (EBS) United States $0.599B 4.71
Zymeworks (ZYME) Canada $0.478B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.278B 0.00
Enzo Biochem (ENZ) United States $0.096B 0.00
SQZ Biotechnologies (SQZ) United States $0.046B 0.00
Gelesis Holdings (GLS) United States $0.035B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00